Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 11/20 | 0.59 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.50 |
| ▸ | HTR3B | O95264 | 1/20 | 0.50 |
| ▸ | HTR3A | P46098 | 1/20 | 0.50 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.50 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.49 |
| ▸ | HTR6 | P50406 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.42 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.42 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6159023 | 0.88 | MEN1 (0.52) | HTR2CSLC6A2SLC6A4SLC6A3MEN1 | |
| SCHEMBL6872023 | 0.88 | PROKR1 (0.44) | HTR2CHTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL2707057 | 0.83 | HTR2C (0.63) | HTR2CSLC6A2SLC6A4SLC6A3HTR6 | |
| SCHEMBL3139821 | 0.83 | PTGDR2 (0.50) | HTR2CMEN1KMT2ACHRNA7 | |
| SCHEMBL1529068 | 0.82 | HTR2C (0.58) | HTR2CSLC6A2SLC6A4SLC6A3HTR6 | |
| SCHEMBL22324792 | 0.82 | HTR2C (0.58) | HTR2CSLC6A2SLC6A4SLC6A3HTR6 | |
| SCHEMBL16446427 | 0.81 | HTR2A (0.59) | HTR2CHTR6MEN1KMT2A | |
| SCHEMBL3542232 | 0.81 | HTR2C (0.47) | HTR2CHTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL24954120 | 0.81 | HTR2C (0.56) | HTR2CSLC6A2SLC6A4SLC6A3HTR6 | |
| SCHEMBL15000426 | 0.80 | HTR2C (0.47) | HTR2CSLC6A2SLC6A4SLC6A3HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210121453-A1 | SELECTIVE NR2B ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2021-04-29 | — | — | US | disclosed |
| US-20200163949-A1 | SELECTIVE NR2B ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2020-05-28 | — | — | US | disclosed |
| US-20190314358-A1 | SELECTIVE NR2B ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2019-10-17 | — | — | US | disclosed |
| US-20190117638-A1 | SELECTIVE NR2B ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2019-04-25 | — | — | US | disclosed |
| US-20180250283-A1 | SELECTIVE NR2B ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2018-09-06 | — | — | US | disclosed |
| EP-3092224-B1 | SELECTIVE NR2B ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2018-08-22 | — | — | EP | disclosed |
| US-20180110766-A1 | SELECTIVE NR2B ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2018-04-26 | — | — | US | disclosed |
| US-20180000807-A1 | SELECTIVE NR2B ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2018-01-04 | — | — | US | disclosed |
| US-20170258777-A1 | Selective NR2B Antagonists | BRISTOL MYERS SQUIBB CO (US) | 2017-09-14 | — | — | US | disclosed |
| EP-3092224-A1 | SELECTIVE NR2B ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2016-11-16 | — | — | EP | disclosed |
| US-20160081995-A1 | Selective NR2B Antagonists | BRISTOL MYERS SQUIBB CO (US) | 2016-03-24 | — | — | US | disclosed |
| US-9221796-B2 | Selective NR2B antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-12-29 | — | — | US | disclosed |
| WO-2015105772-A1 | SELECTIVE NR2B ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-07-16 | — | — | WO | disclosed |
| US-20150191452-A1 | Selective NR2B Antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2015-07-09 | — | — | US | disclosed |
| US-7196199-B2 | Antiserotonine agents; antidepressants | MITSUBISHI PHARMA CORPORATION (JP) | 2007-03-27 | — | — | US | disclosed |
| US-20040138227-A1 | Phenoxypropylamine compounds | NISHIYAMA AKIRA | 2004-07-15 | — | — | US | disclosed |
| US-6720320-B2 | ANTISEROTONINE AGENTS | MITSUBISHI PHARMA CORPORATION (JP) | 2004-04-13 | — | — | US | disclosed |
| US-20020111358-A1 | Phenoxypropylamine compounds | MITSUBISHI PHARMA CORPORATION (JP) | 2002-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138227-A1 | Phenoxypropylamine compounds | HTR1A, HTR1D, HTR5A | HTR2C 9/4885HTR3E 22/4885HTR3B 15/4885 |
| US-20180000807-A1 | SELECTIVE NR2B ANTAGONISTS | GRIN2B, GRIN2A, GRIN3A | HTR2C 94/4885HTR3E 377/4885HTR3B 148/4885 |
| US-20210121453-A1 | SELECTIVE NR2B ANTAGONISTS | GRIN2B, GRIN2A, GRIN3A | HTR2C 94/4885HTR3E 377/4885HTR3B 148/4885 |
| US-20190117638-A1 | SELECTIVE NR2B ANTAGONISTS | GRIN2B, GRIN2A, GRIN3A | HTR2C 94/4885HTR3E 377/4885HTR3B 148/4885 |
| US-20190314358-A1 | SELECTIVE NR2B ANTAGONISTS | GRIN2B, GRIN2A, GRIN3A | HTR2C 94/4885HTR3E 377/4885HTR3B 148/4885 |
| US-20020111358-A1 | Phenoxypropylamine compounds | HTR1A, HTR1D, HTR5A | HTR2C 9/4885HTR3E 22/4885HTR3B 15/4885 |
| US-20150191452-A1 | Selective NR2B Antagonists | GRIN2B, GRIN2A, GRIN3A | HTR2C 94/4885HTR3E 377/4885HTR3B 148/4885 |
| US-20170258777-A1 | Selective NR2B Antagonists | GRIN2B, GRIN2A, GRIN3A | HTR2C 94/4885HTR3E 377/4885HTR3B 148/4885 |
| US-20160081995-A1 | Selective NR2B Antagonists | GRIN2B, GRIN2A, GRIN3A | HTR2C 94/4885HTR3E 377/4885HTR3B 148/4885 |
| US-20180250283-A1 | SELECTIVE NR2B ANTAGONISTS | GRIN2B, GRIN2A, GRIN3A | HTR2C 94/4885HTR3E 377/4885HTR3B 148/4885 |
| US-20180110766-A1 | SELECTIVE NR2B ANTAGONISTS | GRIN2B, GRIN2A, GRIN3A | HTR2C 94/4885HTR3E 377/4885HTR3B 148/4885 |
| US-20200163949-A1 | SELECTIVE NR2B ANTAGONISTS | GRIN2B, GRIN2A, GRIN3A | HTR2C 94/4885HTR3E 377/4885HTR3B 148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.